SCHEMBL6487299

SCHEMBL6487299

COC(=O)c1ccccc1COc1cc(C)c2nc(C)n(Cc3ncc(C(F)(F)F)cc3Cl)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 2/20 0.42
LMNA P02545 2/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 2/20 0.39
TDP1 Q9NUW8 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
BCL2 P10415 4/20 0.37
MCL1 Q07820 4/20 0.37
KDM4E B2RXH2 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GLA P06280 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488861 0.92 BCL2 (0.44) MRGPRX4TDP1L3MBTL1CYP1A2CYP3A4
SCHEMBL6489607 0.91 MEN1 (0.41) MRGPRX4LMNAGAAMAPTTDP1
SCHEMBL6488710 0.90 BCL2 (0.39) MAPTALDH1A1BCL2MCL1
SCHEMBL6490693 0.88 MRGPRX4 (0.43) MRGPRX4LMNAGAAMAPTTDP1
SCHEMBL6499279 0.88 BCL2 (0.38) MAPTBCL2MCL1KMT2A
SCHEMBL6489176 0.88 BCL2 (0.38) MAPTCYP3A4CYP2C19BCL2MCL1
SCHEMBL6490267 0.85 BCL2 (0.38) MAPTBCL2MCL1SMN1; SMN2KMT2A
SCHEMBL7192439 0.84 MRGPRX4 (0.40) MRGPRX4MAPTTDP1L3MBTL1CYP1A2
SCHEMBL6488957 0.83 BCL2 (0.42) MRGPRX4TDP1L3MBTL1BCL2MCL1
SCHEMBL6491005 0.81 BCL2 (0.47) MRGPRX4BCL2MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD MRGPRX4 2443/4885LMNA 3711/4885GAA 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.